The first respiratory syncytial virus (RSV) vaccination has been licenced by the Food and Drug Administration (FDA) of the United States of America for use in pregnant women to safeguard the unborn child. Pfizer produced this vaccine, which can now be administered to pregnant women between 32 and 36 weeks along with other prenatal care to protect against serious illness and lower respiratory tract infections in newborns up until the age of six months. According to the creator of the vaccine, immunisation of mothers could greatly reduce the number of RSV-related hospitalisations. According to reports, the syncytial virus is a frequent cause of illness in children, with newborns being most at risk for developing serious illness.